[1] TANAKA A,MORI M,MATSUMOTO K,et al.Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis,autoimmune hepatitis,and primary sclerosing cholangitis in Japan[J].Hepatol Res,2019,49(8):881-889. [2] SANDUSADEE N,SUKEEPAISARNJAROEN W,SUTTICHAIMONGKOL T.Prognostic factors for remission,relapse,and treatment complications in type 1 autoimmune hepatitis[J]. Heliyon,2020,6(4):e03767. [3] AN J H.Expression and significance of Th17 cells and related factors in patients with autoimmune hepatitis[J]. Comb Chem High Throughput Screen,2019,22(4):232-237. [4] BOVENSIEPEN C S,SCHAKAT M,SEBODE M,et al.TNF-producing Th1 cells are selectively expanded in liver infiltrates of patients with autoimmune hepatitis[J]. J Immunol,2019,203(12):3148-3156. [5] KWAK S Y,LEE S,HAN H D,et al.PLGA nanoparticles codelivering siRNAs against programmed cell death protein-1 and its ligand gene for suppression of colon tumor growth[J]. Mol Pharm,2019,16(12):4940-4953. [6] KIM D H,KIM H,CHOI Y J,et al.Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer[J]. Exp Mol Med,2019,51(8):1-13. [7] AARSLEV K,DIGE A,GREISEN S R,et al.Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis[J]. Scand J Gastroenterol,2017,52(1):93-99. [8] 杨晋辉,章宗籍.自身免疫性肝病[M].北京: 人民卫生出版社,2011:17-18. [9] 彭小燕,徐莉娟,刘鹏,等. 自身免疫性肝炎患者血清腺苷脱氨酶水平与肝组织炎症活动程度的关系及对治疗应答的影响[J]. 实用肝脏病杂志,2019,22(2):200-203. [10] RIGOPOULOU E I,GYFTAKI S,ARVANITI P,et al.Autoimmune hepatitis in patients with multiple sclerosis:the role of immunomodulatory treatment[J]. Clin Res Hepatol Gastroenterol,2019,43(3):e25-e32. [11] MACK C L,ADAMS D,ASSIS D N,et al.Diagnosis and management of autoimmune hepatitis in adults and children:2019 practice guidance and guidelines from the American association for the study of liver diseases[J]. Hepatology,2020,72(2):671-722. [12] CZAJA A J.Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis[J]. Autoimmunity,2019,52(4):144-160. [13] 高美欣,何玲玲,叶小慧,等. Glt25d1基因敲低对刀豆蛋白A诱导的自身免疫性肝炎小鼠巨噬细胞和中性粒细胞的影响[J]. 中国肝脏病杂志(电子版),2020,12(1):36-43. [14] HIRAHARA S,KATSUMATA Y,KAWASUMI H,et al.Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity[J]. Lupus,2020,29(7):686-696. [15] VOORWERK L,SLAGTER M,HORLINGS H M,et al.Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade:the TONIC trial[J]. Nat Med,2019,25(6):920-928. [16] MOCAN T,SPARCHEZ Z,CRACIUN R,et al.Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma:prognostic and therapeutic perspectives[J]. Clin Transl Oncol,2019,21(6):702-712. [17] STEFANSKI A L,WIEDEMANN A,REITER K,et al.Enhanced programmed death 1 and diminished programmed death ligand 1 up-regulation capacity of post-activated lupus B cells[J]. Arthritis Rheumatol,2019,71(9):1539-1544. [18] SUGIURA D,MARUHASHI T,OKAZAKI I M,et al.Restriction of PD-1 function by Cis-PD-L1/CD80 interactions is required for optimal T cell responses[J]. Science,2019,364(6440):558-566. [19] AGINA H A,EHSAN N A,ABD-ELAZIZ T A,et al. Hepatic expression of programmed death-1 (PD-1) and its ligand,PD-L1,in children with autoimmune hepatitis:relation to treatment response[J]. Clin Exp Hepatol,2019,5(3):256-264. [20] BEHAIRY O G,BEHIRY E G,EL DEFRAWY M S,et al. Diagnostic value of soluble programmed cell death protein-1 in type-1 autoimmune hepatitis in Egyptian children[J]. Scand J Clin Lab Invest,2020,80(1):59-65. [21] 何启军,符火,陈扬,等. 肝组织中程序性死亡受体1与自身免疫性肝炎炎性反应的关系[J]. 肝脏,2019,24(7):756-760. [22] PEREZ-RUIZ E,MINUTE L,OTANO I,et al.Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy[J]. Nature,2019,569(7756):428-432. [23] JENNINGS J J,MANDALIYA R,NAKSHABANDI A,et al.Hepatotoxicity induced by immune checkpoint inhibitors:a comprehensive review including current and alternative management strategies[J]. Expert Opin Drug Metab Toxicol,2019,15(3):231-244. [24] 芮志莲. 自身免疫性肝炎患者外周血CD8+T细胞PD-1表达水平变化[J]. 实用肝脏病杂志,2017,20(3):352-353. [25] 熊克宫,柯坤宇,孔金峰,等. 1型自身免疫性肝炎患者外周血T淋巴细胞PD-L1的表达情况及其与肝脏炎症活动度的相关性分析[J]. 临床肝胆病杂志,2018,34(6):1248-1252. [26] JOSHITA S,YOSHIZAWA K,UMEMURA T,et al.Clinical features of autoimmune hepatitis with acute presentation:a Japanese nationwide survey[J]. J Gastroenterol,2018,53(9):1079-1088. [27] LIU L Y,CAO J Y,ZHONG Z R,et al.Noninvasive indicators predict advanced liver fibrosis in autoimmune hepatitis patients[J]. J Clin Lab Anal,2019,33(7):e22922. [28] 柯坤宇,熊克宫,魏大海,等. 自身免疫性肝炎患者肝组织程序性细胞死亡因子配体1的表达及其与肝功能的相关性[J]. 中华传染病杂志,2016,34(10):577-581. [29] 廖永强,孟芳,肖妮,等. PD-L1和IFN-ɑ与系统性红斑狼疮患者免疫功能异常的关系研究[J]. 中国免疫学杂志,2020,36(16):2016-2019. [30] LU J C,ZENG H Y,SUN Q M,et al.Distinct PD-L1/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors[J]. Theranostics,2019,9(16):4678-4687. [31] 林兰,沈敏,阮健文. 自身免疫性肝炎患者肝组织程序性死亡受体1表达及其临床意义探讨[J]. 实用肝脏病杂志,2019,22(2):204-207. |